A Historic Gold Announcement Is About to Rock Wall Street

The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent - and four tiny miners could be your ticket to 100X gains.

South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs

GERALD IMRAY and MARIA CHENG
November 24, 2023

CAPE TOWN, South Africa (AP) -- South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV.

Experts see it as a shift in how such countries deal with pharmaceutical behemoths and say it could trigger more efforts to make lifesaving medicines more widely available.

In the COVID-19 pandemic, rich countries bought most of the world's vaccines early, leaving few shots for poor countries and creating a disparity the World Health Organization called "a catastrophic moral failure."

Now, poorer countries are trying to become more self-reliant "because they've realized after COVID they can't count on anyone else," said Brook Baker, who studies treatment-access issues at Northeastern University.

One of the targets is a drug, bedaquiline, that is used for treating people with drug-resistant versions of tuberculosis. The pills are especially important for South Africa, where TB killed more than 50,000 people in 2021, making it the country's leading cause of death.

In recent months, activists have protested efforts by Johnson & Johnson to protect its patent on the drug. In March, TB patients petitioned the Indian government, calling for cheaper generics; the government ultimately agreed J&J's patent could be broken. Belarus and Ukraine then wrote to J&J, also asking it to drop its patents, but with little response.

In July, J&J's patent on the drug expired in South Africa, but the company had it extended until 2027, enraging activists who accused it of profiteering.

The South African government then began investigating the company's pricing policies. It had been paying about 5,400 rand ($282) per treatment course, more than twice as much as poor countries that got the drug via a global effort called the Stop TB partnership.

In September, about a week after South Africa's probe began, J&J announced that it would drop its patent in more than 130 countries, allowing generic-makers to copy the drug.

"This addresses any misconception that access to our medicines is limited," the company said.

Christophe Perrin, a TB expert at Doctors Without Borders, called J&J's reversal "a big surprise" because aggressive patent protection was typically a "cornerstone" of pharmaceutical companies' strategy.

Meanwhile, in Colombia, the government declared last month that it would issue a compulsory license for the HIV drug dolutegravir without permission from the drug's patent-holder, Viiv Healthcare. The decision came after more than 120 groups asked the Colombian government to expand access to the WHO-recommended drug.

"This is Colombia taking the reins after the extreme inequity of COVID and challenging a major pharmaceutical to ensure affordable AIDS treatment for its people," said Peter Maybarduk of the Washington advocacy group Public Citizen. He noted that Brazilian activists are pushing their government to make a similar move.

Still, some experts said much more needs to change before poorer countries can produce their own medicines and vaccines.

When the coronavirus pandemic hit, Africa produced fewer than 1% of all vaccines made globally but used more than half of the world's supply, according to Petro Terblanche, managing director of Afrigen Biologics. The company is part of a WHO-backed effort to produce a COVID vaccine using the same mRNA technology as those made by Pfizer and Moderna.

Terblanche estimated about 14 million people died of AIDS in Africa in the late 1990s-2000s, when countries couldn't get the necessary medicines.

Back then, President Nelson Mandela's government in South Africa eventually suspended patents to allow wider access to AIDS drugs. That prompted more than 30 drugmakers to take it to court in 1998, in a case dubbed "Mandela vs. Big Pharma."

Doctors Without Borders described the episode as "a public relations disaster" for the drug companies, which dropped the lawsuit in 2001.

Terblanche said that Africa's past experience during the HIV epidemic has proven instructive.

"It's not acceptable for a listed company to hold intellectual property that stands in the way of saving lives and so, we will see more countries fighting back," she said.

Challenging pharmaceutical companies is just one piece to ensuring Africa has equal access to treatments and vaccines, Terblanche said. More robust health systems are critical.

"If we can't get (vaccines and medicines) to the people who need them, they aren't useful," she said.

Yet some experts pointed out that South Africa's own intellectual property laws still haven't been changed sufficiently and make it too easy for pharmaceutical companies to acquire patents and extend their monopolies.

While many other developing countries allow legal challenges to a patent or a patent extension, South Africa has no clear law that allows it to do that, said Lynette Keneilwe Mabote-Eyde, a health care activist who consults for the nonprofit Treatment Action Group.

The South African department of health didn't respond to a request for comment regarding drug procurement and patents.

Andy Gray, who advises the South African government on essential medicines, said J&J's recent decision to not enforce its patent may have more to do with the drug's limited future earnings than caving to pressure from activists.

"Because bedaquiline is not ever going to sell in huge volumes in high-income countries, it's the sort of product they would love to offload at some stage and perhaps earn a royalty from," said Gray, a senior lecturer in pharmacology at the University of KwaZulu-Natal.

In its annual report on TB released earlier this month, the World Health Organization said there were more than 10 million people sickened by the disease last year and 1.3 million deaths. After COVID-19, tuberculosis is the world's deadliest infectious disease and it is now the top killer of people with HIV. WHO noted only about 2 in 5 people with drug-resistant TB are being treated.

Zolelwa Sifumba, a South African doctor, was diagnosed with drug-resistant TB in 2012 when she was a medical student and endured 18 months of treatment taking about 20 pills every day in addition to daily injections, which left her in "immense pain" and resulted in some hearing loss. Bedaquiline was not rolled out as a standard treatment in South Africa until 2018.

"I wanted to quit (treatment) every single day," she said. Since her recovery, Sifumba has become an advocate for better TB treatment, saying it makes little sense to charge poor countries high prices for essential medicines.

"TB is everywhere but the burden of it is in your lower and middle income countries," she said. "If the lower income countries can't get it (the drug), then what's the point? Who are you making it for?"

___

Cheng reported from London.

___

AP health coverage: https://apnews.com/health

Continue Reading...

Popular

Trump's 'Big, Beautiful Bill' Offers Seniors A $6,000 'Bonus' Tax Deduction: Here's How You Qualify For The Benefit

Trump's Big, Beautiful Bill offers a $6,000 senior bonus deduction from 2025-28. Couples can save $12,000. Retirees with incomes up to $75,000 benefit most.

FDA Submission Expected This Summer - Invest Before It Happens - Ad

This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.

A strike by air traffic controllers is disrupting travel to, from and over France

PARIS (AP) — About 40% of flights were canceled Friday at all Paris airports and tens of thousands of passengers were rearranging plans at the height of the summer travel season because of a strike by French seeking better working conditions.

Back This Medical AI Tech - Ad

You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.

Cathie Wood's Alpha Surge: $250 Million Circle Windfall, Big AMD Buys

Cathie Wood, founder and CEO of ARK Invest, has recently been on a hot streak of successful and high-profile trades through her flagship ARK ETFs. 

Is a Deliberate "Dollar Reset" Already Underway? - Ad

In an office building across the street from the White House, a powerful unelected official has laid out a plan that could deliberately tank the U.S. dollar, which could wipe out decades of retirement wealth for millions of unsuspecting Americans. A new video explains how. It lays out four urgent steps you should take immediately.

Iran’s president orders country to suspend cooperation with UN nuclear watchdog IAEA

DUBAI, United Arab Emirates (AP) — Iran’s president on Wednesday ordered the country to suspend its cooperation with after American and Israeli airstrikes hit its most-important nuclear facilities, likely further limiting inspectors' ability to track Tehran's program that had been enriching uranium to near weapons-grade levels.

Meta, KKR, Lululemon And An Industrial Stock On CNBC's 'Final Trades'

Experts predict KKR, Lululemon, Meta Platforms, and Rockwell Automation to perform well.

How to Hack a $1.3T Market - Ad

Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.

Diddy Jury Deadlocked On Racketeering Conspiracy Charge As Verdicts Reached On Sex Trafficking Counts — Jurors To Return Wednesday

Jurors in Sean "Diddy" Combs' trial reached verdicts on four charges related to sex trafficking but remain deadlocked on the racketeering conspiracy charge, with deliberations set to continue.

The Unlikely Duo Rethinking Wearable Technology - Ad

Why did a surgeon and Snap exec team up? They saw the missing ingredient in the $84T wearables market: behavior. So they built Emteq and invented smart glasses sensors to track real-time expressions, unlocking insights into why we do things. With a $15M term sheet already secured, Emteq is what Big Tech's missing.

Mystery Seller Behind $105 Million Plot Next to Jeff Bezos Estate Finally Revealed

A plot of land neighboring Jeff Bezos' property in Miami was sold for a staggering $105 million. The undeveloped lot was sold by German investor Mikhail Peleg.

The Missing Ingredient for Big Tech's $3T Recipe? - Ad

Big Tech doesn't build everything; they buy what's next. And only Emteq's tech offers real behavior insights for smart glasses, key to unlocking the $3T XR market. Their patented sensors track live facial muscle movements. With health-focused smart glasses in demand, only Emteq has this tech.

Trump vents online about service provider after conference call marred by glitch

WASHINGTON (AP) — On Monday afternoon, the president of the United States was just another person complaining online about his service provider.

BigBear.ai, AMD, QuantumScape, Coinbase, Tesla: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks ended the day on a high note, with the Nasdaq gaining over 1.4% on Tuesday to 19,912.53. The Dow also traded up 1.2% to 43,089.02, while the S&P 500 rose by 1.1% to 6,092.18. These are the top stocks that gained the attention of retail traders and investors throughout the day:

The Tesla Shock Nobody Sees Coming - Ad

While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.

US brings charges in North Korean remote worker scheme that officials say funds weapons program

WASHINGTON (AP) — The Justice Department announced criminal charges Monday in connection with a scheme by North Korea to fund its weapons program through the salaries of remote information technology workers employed unwittingly by U.S. companies.

California-Trump Legal Battle Over National Guard Deployment Escalates After Court Ruling

California's legal battle with Trump over military deployment in LA is at a standstill after an appeals court ruled in Trump's favor.

Is Elon's Empire Crumbling? - Ad

Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after July 23rd, it may be too late.

CoreWeave Stock Rallied On Thursday: What Happened?

Shares of CoreWeave Inc. (NASDAQ: CRWV) traded higher on Thursday with gains accelerating into the close. The company announced it became the first AI cloud provider to deploy NVIDIA Corp's (NASDAQ:NVDA) new GB300 NVL72 platform.

Royal Caribbean Cruises Stock Up 0.9% After Key Trading Signal

A significant trading signal occurred for Royal Caribbean Cruises stock at a price of $331.57, after which RCL rose up to 0.9%.

Our No.1 AI Stock Has Nothing to Do With Tech - Ad

Nvidia CEO Jensen Huang recently said AI requires "100 times more" power. We believe that means the best way to invest in AI right now has nothing to do with technology ... And everything to do with energy. One stock appears to be perfectly positioned...

How to manage ADHD at work and turn it into a strength

NEW YORK (AP) — Jeremy Didier had taken her son to a psychologist for a when she spotted an article about women with the condition. As she read it in the waiting room, she thought to herself: They're describing me.

FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff

WASHINGTON (AP) — The working under Health Secretary recently of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released Wednesday.

A Historic Gold Announcement Is About to Rock Wall Street - Ad

The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent - and four tiny miners could be your ticket to 100X gains.

What's in the latest version of Trump's big bill moving through the Senate

WASHINGTON (AP) — Republicans are inching closer to getting their tax and spending cut bill through Congress with a final Senate vote likely late Monday or early Tuesday.

Elon Musk Says 'Clear Path' To Restoring Hearing With Neuralink, But The Deaf Community Want To Have Their 'Say'

Elon Musk's Neuralink faces backlash from the deaf community after proposing brain implant technology to restore hearing, with deaf adults calling for inclusion in the research process.

FDA Submission Expected This Summer - Invest Before It Happens - Ad

This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.

Trump's Approval Ratings, Tariff Deadlines, Schumer's Criticism, And Defense Budget Shifts: This Week In Politics

Trump's approval ratings drop after Iran attack, hints at tariff deadline flexibility. SC limits judges' power, Schumer criticizes GOP budget, defense budget shifts to missiles and drones.

Denmark tests unmanned robotic sailboat fleet with tensions high in the region

KOGE MARINA, Denmark (AP) — From a distance they look almost like ordinary sailboats, their sails emblazoned with the red-and-white flag .

Back This Medical AI Tech - Ad

You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.

BigBear.ai (BBAI) Stock Soars 21%: What's Going On?

Shares of BigBear.ai are trading sharply higher Tuesday afternoon. The rally comes without any new company-specific announcements.

Sig Sauer, faced with lawsuits over a popular pistol, gets protection in New Hampshire

CONCORD, N.H. (AP) — Faced with mounting lawsuits over a popular pistol, New Hampshire-based Sig Sauer asked for — and got — protection in the form of a new state law that makes it harder to .

Is a Deliberate "Dollar Reset" Already Underway? - Ad

In an office building across the street from the White House, a powerful unelected official has laid out a plan that could deliberately tank the U.S. dollar, which could wipe out decades of retirement wealth for millions of unsuspecting Americans. A new video explains how. It lays out four urgent steps you should take immediately.

Trump ramps up attacks on the Federal Reserve but Powell sticks to 'wait and see' stance

WASHINGTON (AP) — Federal Reserve Chair Jerome Powell on Tuesday stuck to that the central bank will keep its key rate on hold while it waits to see how President Donald Trump's effect the economy, despite the from the White House, which wants lower borrowing costs.

Trending Now

Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.

Copyright trendadvisor.net
Privacy Policy | Terms of Service